An assessment of physician reasons for prescribing Insulin Lispro 200 units/ml in Germany

References

• Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–2251.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant P, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. 2019.
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 9th edition. Brussels, Belgium: 2019. Available at: https://www.diabetesatlas.org
   Google Scholar
• Freeland B, Farber MS. A Review of Insulin for the Treatment of Diabetes Mellitus. Home Healthc Now. 2016;34(8):416–423.
   PubMedGoogle Scholar
• Kalra S. High Concentration Insulin. Indian J Endocrinol Metab. 2018;22(1):160–163.
   PubMedGoogle Scholar
• Rees TM, Lennartz AH, Ignaut DA. A comparison of glide force characteristics between 2 prefilled insulin lispro pens. J Diabetes Sci Technol. 2015;9(2):316–319.
   PubMedGoogle Scholar
• Watson L, Wilson BP, Alsop J, et al. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation? Diabetes Obes Metab. 2011;13(9):823–831.
   PubMed Web of Science ®Google Scholar
• Group IDFDA. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2013. Diabetes Res Clin Pract. 2015;109(3):461–465.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectr. 2012;35(6):1364–1379.
   Google Scholar
• Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obesity. 2008;32(9):1431–1437.
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014;16(10):971–976.
   PubMed Web of Science ®Google Scholar
• Lee LJ, Li Q, Reynolds MW, et al. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ. 2011;14(1):75–86.
   PubMedGoogle Scholar
• Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307.
   PubMed Web of Science ®Google Scholar
• Schloot NC, Hood RC, Corrigan SM, et al. Concentrated insulins in current clinical practice. Diabetes Res Clin Pract. 2019;148:93–101.
   PubMed Web of Science ®Google Scholar
• Segal AR, El Sayed N. Are you ready for more insulin concentrations? J Diabetes Sci Technol. 2015;9(2):331–338.
   PubMedGoogle Scholar
• de la Pena A, Seger M, Soon D, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog(R)) 100 U/mL. Clin Pharmacol Drug Dev. 2016;5(1):69–75.
   PubMed Web of Science ®Google Scholar
• Wang T, Conrad KA, van Brunt K, et al. Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin. J Diabetes Sci Technol. 2016;10(4):923–931.
   PubMedGoogle Scholar
• Barry MJ, Edgman-Levitan S. Shared decision making–pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–781.
   PubMed Web of Science ®Google Scholar
• Spatz ES, Spertus JA. Shared decision making: a path toward improved patient-centered outcomes. Circ Cardiovasc Qual Outcomes. 2012;5(6):e75–7.
   PubMed Web of Science ®Google Scholar
• Gentile S, Fusco A, Colarusso S, et al. A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. Expert Opin Drug Saf. 2018;17(5):445–450.
   PubMed Web of Science ®Google Scholar
• Heinemann L, Beals JM, Malone J, et al. Concentrated insulins: history and critical reappraisal. J Diabetes. 2019;11(4):292–300.
   PubMed Web of Science ®Google Scholar
• Hood RC. Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile? Diabetes Technol Ther. 2017;19(4):203–205.
   PubMed Web of Science ®Google Scholar
• Grant RW, Wexler DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care. 2007;30(6):1448–1453.
   PubMed Web of Science ®Google Scholar
• Porzsolt F, Clouth J, Deutschmann M, et al. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes. 2010;8:125.
   PubMed Web of Science ®Google Scholar
• Van Brunt K, Pedersini R, Rooney J, et al. Behaviours, thoughts and perceptions around mealtime insulin usage and wastage among people with type 1 and type 2 diabetes mellitus: A cross-sectional survey study. Diabetes Res Clin Pract. 2017;126:30–42.
   PubMed Web of Science ®Google Scholar
• Boye KS, Curtis SE, Lage MJ, et al. Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherence. 2016;10:1573–1581.
   PubMed Web of Science ®Google Scholar
• Egede LE, Gebregziabher M, Dismuke CE, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35(12):2533–2539.
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence. 2017;11:1103–1117.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–689.
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100(6):345–350.
   PubMed Web of Science ®Google Scholar
• Lutfey KE, Campbell SM, Renfrew MR, et al. How are patient characteristics relevant for physicians’ clinical decision making in diabetes? An analysis of qualitative results from a cross-national factorial experiment. Soc Sci Med. 2008;67(9):1391–1399.
   PubMed Web of Science ®Google Scholar
• Grant RW, Lutfey KE, Gerstenberger E, et al. The decision to intensify therapy in patients with type 2 diabetes: results from an experiment using a clinical case vignette. J Am Board Fam Med. 2009;22(5):513–520.
   PubMed Web of Science ®Google Scholar
• VanGeest JB, Johnson TP, Welch VL. Methodologies for improving response rates in surveys of physicians: a systematic review. Eval Health Prof. 2007;30(4):303–321.
   PubMed Web of Science ®Google Scholar